Loading
A phase 3 trial of Nivolumab, Epacadostat, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel / nab-paclitaxel and Pemetrexed in Lung cancer, run by Incyte Corporation, recorded as terminated on the registry.
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT03348904 by Incyte Corporation, with 2 participants recorded, started 2017-12-27 and due to reach its primary completion in 2018-05-22. Interventions recorded: Nivolumab, Epacadostat, Placebo, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Pemetrexed. Conditions recorded: Lung Cancer.
Linked to the drug Epacadostat because the registry names it among its interventions and Lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Epacadostat, Incyte, Cisplatin, Carboplatin and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin, Lung cancer (all types) and the tag pipeline.
Shares Epacadostat, Incyte and the tag pipeline.
Shares Pemetrexed, Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Gemcitabine, Cisplatin and the tag pipeline.
Shares Gemcitabine, Nivolumab, Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin and the tag pipeline.
Shares Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/